Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 80 and over Aged. Found 174 abstracts

no pagination
Koutrouli N, Anagnostopoulos F, Tsikkinis A, Papastylianou D, Lepore S. Psychometric properties of the Greek version of the Social Constraints Scale in a sample of women with breast cancer. Women Health. 2016 Jan;56(4):413-27.
Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys. 2016 Mar;94(3):554-60.   PMCID: 4876948
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Nov 11;22(1):34-43.
Balamucki CJ, DeJesus R, Galloway TJ, Mancuso AA, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM. Impact of radiographic findings on for prognosis skin cancer with perineural invasion. Am J Clin Oncol. 2015 Jun;38(3):248-51.
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun;137(3):386-91.   PMCID: 4447525
Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr;121(7):1032-9.
Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M, Lawton CA, Sandler HM. Impact of Biochemical Failure Classification on Clinical Outcome: A Secondary Analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar;121(6):844-52.   PMCID: 4657945
Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15;21(16):3610-8.   PMCID: 4790106
Mehrazin R, Uzzo RG, Kutikov A, Ruth K, Tomaszewski JJ, Dulaimi E, Ginzburg S, Abbosh PH, Ito T, Corcoran AT, Chen DY, Smaldone MC, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations. 2015 Sep;33(9):388e19-388e25.   PMCID: 4289664
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 05;373(19):1803-13.
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder DB, Ridge JA. Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database. Cancer. 2015 Apr 15;121(8):1204-13.
Occhipinti S, Chambers SK, Lepore S, Aitken J, Dunn J. A Longitudinal Study of Post-Traumatic Growth and Psychological Distress in Colorectal Cancer Survivors. PLoS One. 2015 Jan;10(9):e0139119.   PMCID: 4587909
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015 Jan 08;125(2):236-41.   PMCID: PMC4287635
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Powers BD, Montes JA, Nguyen DC, Nick DA, Daly MP, Davey A, Willis AI. Demographic risk factors impacting timely radiation therapy completion after breast conserving surgery. Am J Surg. 2015 Nov;210(5):891-5.
Revenig LM, Canter DJ, Henderson MA, Ogan K, Kooby DA, Maithel SK, Liu Y, Kim S, Master VA. Preoperative quantification of perceptions of surgical frailty. J Surg Res. 2015 Feb;193(2):583-9.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46.   PMCID: 4562797
Wang EH, Yu JB, Gross CP, Abouassaly R, Cherullo EE, Smaldone MC, Shah ND, Kiechle J, Trinh QD, Sun M, Kim SP. Association between Surgeon and Hospital Characteristics and Lymph Node Counts From Radical Prostatectomy and Pelvic Lymph Node Dissection. Urology. 2015 Apr;85(4):890-5.
Wang EH, Yu JB, Gross CP, Smaldone MC, Shah ND, Trinh QD, Nguyen PL, Sun M, Han LC, Kim SP. Variation in pelvic lymph node dissection among patients undergoing radical prostatectomy by hospital characteristics and surgical approach: results from the National Cancer Database. J Urol. 2015 Mar;193(3):820-5.
Wang LS, Shaikh T, Handorf EA, Hoffman JP, Cohen SJ, Meyer JE. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Pract Radiat Oncol. 2015 Sep;5(5):e457-63.   PMCID: 4814166
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 80 and over Aged

Middle Aged 80 and over Aged Aged Adult Male Female pathology drug therapy therapeutic use mortality methods Prognosis Chemoradiotherapy adverse effects Young Adult radiotherapy therapy Prostatic Neoplasms Antineoplastic Agents Kaplan-Meier Estimate genetics Quality of Life statistics & numerical data administration & dosage Prospective Studies analogs & derivatives Multivariate Analysis blood Follow-Up Studies Treatment Outcome Surveys and Questionnaires Squamous Cell Carcinoma Prostatectomy Factual Databases Age Factors Survival Rate Neoplasm Invasiveness Reproducibility of Results Doxorubicin Prednisone Head and Neck Neoplasms Monoclonal Antibodies Adenocarcinoma Cyclophosphamide surgery psychology Breast cancer Neoadjuvant Therapy Retrospective Studies Kidney Neoplasms Renal Cell Carcinoma Pelvis Breast Neoplasms High-Volume Hospitals United States Low-Volume Hospitals Local Neoplasm Recurrence Vincristine Prostate-Specific Antigen Antineoplastic Combined Chemotherapy Protocols Disease-Free Survival Biomarkers Lymph Node Excision Proportional Hazards Models Pancreatic Neoplasms Combined Modality Therapy Psychological Stress National Cancer Database cyclophosphamide Outcomes Kallikreins Rb1 One more Maximum Tolerated Dose Urothelial carcinoma Socioeconomic Factors Skin Neoplasms epidemiology Survival Analysis Frail Elderly Statistical Factor Analysis Toxicity Community Hospitals Ovarian cancer Genotype head and neck cancer Veliparib Cisplatin Psychometrics Medicaid radiography Lymphocyte count DNA Repair Fallopian Tube Neoplasms lymph node excision Dose Fractionation Nonparametric Statistics Patient attitudes treatment outcome consolidation Magnetic Resonance Imaging Social Constraints Scale Dacarbazine Taxoids Renal cell carcinoma Piperidines dosage Papillary renal cell carcinoma Karnofsky Performance Status Registries Hospitals Medicare Robotics doxorubicin Radiotherapy Dosage Translating Disparities intrusions Radiotherapy Genetic Polymorphism Urinary Bladder Neoplasms Atm Combination Drug Therapy Lymph Nodes Peripheral Nerves Quinazolines Adolescent Survival Fancc Neoplasm Drug Resistance Fluorouracil Rituximab Retreatment Neutropenia immunology BRCA2 Genes Androgen Antagonists Postoperative Complications Monoclonal Antibodies-Murine-Derived BRCA1 Genes diagnosis chemically induced Treatment Failure BRCA2 Protein Surgery physiology organization & administration Cisplatin resistance Germ-Line Mutation Risk Factors
Last updated on Friday, December 02, 2016